The thymus is a bilobed organ sitting in the upper anterior mediastinum, behind the sternum and in front of the heart. Unlike most organs, it is big in childhood and shrinks as you age — from roughly 30-40 g in infancy to a few grams of fat-infiltrated remnant by 60. Its job is finished, or nearly so, by the time most adults even become aware it exists. But what it does in those early decades sets the shape of your immune repertoire for life.
At a glance
What it does
Makes functional T cells. Immature lymphoid precursors leave the bone marrow, arrive in the thymus, and undergo the complex education process that turns them into T cells capable of recognizing foreign antigens without attacking self. The organ is organized into cortex (dense with immature thymocytes) and medulla (where the final selection steps happen), with thymic epithelial cells serving as the teachers.
Two selections matter. Positive selection: thymocytes that can recognize self-MHC get a survival signal; those that cannot die. Negative selection: thymocytes that recognize self-antigen too strongly are deleted, preventing autoimmunity. The surviving cells — roughly 1-5% of those that entered — leave as naive T cells and populate peripheral lymphoid tissues for the rest of your life.
The medullary thymic epithelial cells express a remarkable array of self-antigens under the control of AIRE (autoimmune regulator), exposing developing T cells to proteins they would only ever encounter in other tissues. Mutations in AIRE cause APECED syndrome — broad autoimmunity because self-tolerance education fails.
How it works
Thymic output is highest in infancy and early childhood and declines across life. This is called thymic involution, and it starts before puberty, accelerates through adulthood, and by old age the thymus is largely replaced by fat with small islands of residual functional tissue. The peripheral T cell pool is maintained primarily by homeostatic proliferation of existing clones rather than by ongoing thymic output.
Hassall's corpuscles are histologic landmarks in the medulla — concentric arrangements of keratinized epithelial cells. They contribute to regulatory T cell development and are used by pathologists to confirm thymic tissue identity.
The thymus secretes several peptides — thymosin-alpha-1, thymopoietin, thymulin, and others — that modulate T cell maturation locally and have been explored as pharmacological agents. Thymosin-alpha-1 is in clinical use in some countries for chronic hepatitis and as an immunomodulator in sepsis, with variable evidence.
When it goes wrong
DiGeorge syndrome (22q11.2 deletion) includes thymic aplasia or hypoplasia — severe cases produce profound T cell deficiency, which is a pediatric immunology emergency treatable by thymic transplant in specialized centers.
Thymoma is the main thymic tumor — typically an indolent epithelial neoplasm, surgical in approach, and famously associated with myasthenia gravis in about 30-45% of patients. Myasthenia gravis is an autoimmune disease against the acetylcholine receptor at the neuromuscular junction, and thymectomy improves outcomes even in non-thymomatous cases.
Thymic involution is not a disease — it is a normal aging process — but it has downstream consequences. Reduced thymic output contributes to the narrowed T cell repertoire of old age, which is one reason the elderly respond less well to new infections and new vaccines. Flu and COVID vaccines produce smaller, less durable responses in older adults partly because they have fewer naive T cells available to recognize novel antigens. Restoring thymic function in adulthood is an active but still preliminary area of research.
Interactions
Sex steroids accelerate thymic involution. Testosterone and estrogen both contribute, which is why castration can transiently regrow thymic tissue and thymic function in animal models and some human studies. Growth hormone, IGF-1, and ghrelin have modest restorative effects in preclinical work. The TRIIM trial (Thymus Regeneration, Immunorestoration, and Insulin Mitigation) in 2019 showed a combination of growth hormone, DHEA, and metformin produced measurable thymic re-expansion on MRI and naive T cell output changes in a small cohort of older men; replication and clinical significance remain uncertain.
BPC-157 and other peptides with some regenerative claims get discussed in this context, though thymic-specific evidence in humans is limited. Thymosin-alpha-1 has the most actual clinical trial data of the thymic peptides, mostly for viral hepatitis and certain cancer adjunctive settings.
Honest take
The thymus is doing serious work until puberty and essentially finishing its career by your 40s. Most "boost your thymus" products are selling nothing — there is no supplement that meaningfully reactivates an involuted thymus, and the serious research into thymic restoration uses growth hormone and other prescription agents with real risks and modest demonstrated effect. The practical takeaway is upstream: vaccinate your kids while their thymus is at full power, get your boosters on schedule as an adult because your repertoire is narrower than it used to be, and do not chase unregulated peptide sources with claims their manufacturers cannot back up.
Sources
- Fahy et al., Aging Cell (2019) — TRIIM trial on thymic regeneration.
- Palmer, Trends in Immunology — the immunology of aging.
- Wolfe et al., Neurology — MGTX randomized trial of thymectomy in non-thymomatous myasthenia gravis.